Enveric Biosciences, Inc. (ENVB) News
Track canonical SquawkNews coverage tagged to ENVB, Enveric Biosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
ENVB - Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
ENVB - Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
NEWS | Sep 15, 2026, 12:05 PM UTC
L
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced tha
NEWS | Sep 15, 2026, 12:01 PM UTC
L
Enveric Biosciences to present at H.C. Wainwright conference
Enveric Biosciences says it will present at H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 01, 2026, 12:38 PM UTC
L
Enveric Biosciences CEO Joseph Tucker to deliver virtual conference presentation
Enveric Biosciences said Joseph Tucker, Ph.D., its CEO, will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 01, 2026, 12:30 PM UTC
L
Enveric Biosciences reports Q2 2026 financial results, corporate update
Enveric Biosciences (ENVB) reports financial results and provides a corporate update for second quarter 2026.
EARNINGS | Aug 14, 2026, 08:12 PM UTC
H
Enveric Biosciences Announces New Preclinical Data That Further Supports The Non-Hallucinogenic Profile Of EB-003; GloSensor Assay Findings
Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay, which has been previously described in peer-reviewed scientific literature (Wang et al., 2022)1. The Promega GloSensor
REGULATION | Aug 05, 2026, 12:08 PM UTC
M
Enveric Biosciences Reports Non-Hallucinogenic Data
Enveric Biosciences reports preclinical data on EB-003
EQUITY | Aug 05, 2026, 12:02 PM UTC
L
Enveric 'welcomes' final FDA guidance for psychedelic drug development
Enveric Biosciences...
EARNINGS | Jul 28, 2026, 12:05 PM UTC